Presentation is loading. Please wait.

Presentation is loading. Please wait.

Philip J. Barter, et al. Circulation 2011;124:555-562.

Published byWarren Alexander Modified over 9 years ago

Similar presentations

Presentation on theme: "Philip J. Barter, et al. Circulation 2011;124:555-562."— Presentation transcript:

1 Philip J. Barter, et al. Circulation 2011;124:555-562

2 Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part I Philip J. Barter, et al. Circulation 2011;124:555-562

3 Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part II Philip J. Barter, et al. Circulation 2011;124:555-562

4 Effects of Treatment With Atorvastatin vs the Combination of Atorvastatin and Torcetrapib on Plasma Glucose, Hemoglobin A 1c, Serum Insulin, HOMA-IR, and HDL Cholesterol for the Subgroup of Diabetic Subjects Philip J. Barter, et al. Circulation 2011;124:555-562

5 Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A 1c, and HOMA-IR Adjusted for Change in HDL Cholesterol - I Philip J. Barter, et al. Circulation 2011;124:555-562

6 Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A 1c, and HOMA-IR Adjusted for Change in HDL Cholesterol - II

7 Effects of Treatment With Atorvastatin vs the Combination of Atorvastatin and Torcetrapib on Plasma Glucose, Hemoglobin A 1c, Serum Insulin, HOMA-IR, and HDL Cholesterol for the Subgroup of Nondiabetic Subjects Philip J. Barter, et al. Circulation 2011;124:555-562

8 CLINICAL PERSPECTIVE Philip J. Barter, et al. Circulation 2011;124:555-562

Download ppt "Philip J. Barter, et al. Circulation 2011;124:555-562."

Similar presentations

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
 High density lipoproteins (HDL) protect against cardiovascular disease  A novel mechanism for raising HDL levels is to inhibit a protein known as CETP.

 High density lipoproteins (HDL) protect against cardiovascular disease  A novel mechanism for raising HDL levels is to inhibit a protein known as CETP.
Downloaded from www.ezetrol.aewww.ezetrol.ae Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.
OLSON, M.L., ET AL Vitamin D Deficiency in Obese Children an Its Relationship to Glucose Homeostasis J Clin Endocrinol Metab, 97, 279-285, 2012.

OLSON, M.L., ET AL Vitamin D Deficiency in Obese Children an Its Relationship to Glucose Homeostasis J Clin Endocrinol Metab, 97, , 2012.
Solomon Tesfaye et al N Engl J Med 2005;352:341- 50 Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.
Westerweel PE et al. Eur Heart J 2008;29:

Westerweel PE et al. Eur Heart J 2008;29:
Independent variables (baseline) Loge (HOMA-IR) b P

Independent variables (baseline) Loge (HOMA-IR) b P
Baseline Characteristics of the Patients Part I

Baseline Characteristics of the Patients Part I
Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517.

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.
Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:1388-1394.

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Similar presentations

Ads by Google